The team of specialists at
In the follow-up CT scans, the patients had shown almost a 50% decrease in tumour mass. Both patients are ambulatory and capable of self-care with no pain and are not on analgesics.
After seeing the promising achieved results, the
A press conference is planned in the coming weeks by Ulis researchers to interact with the media and attract other researchers to collaborate and explore the full potential of the novel TSE technology.
"Almost five months after treatment the response of our patients seems lasting and we are optimistic that it can sustain for many more months, with a positive impact on overall survival. We would like to invite cancer researchers internationally to join hands with us in our pursuit of exploring the TSE technology further, possibly in combination with immune-oncology drugs. "- says
"We are optimistic and the medical team at ChemoTech will continue to observe the data meticulously for safety, efficacy, and additional indications." - says Dr
The global pancreatic cancer market will be valued at around
About Tumour Specific Electroporation(TM) - TSE
TSE is a patented tumour-specific technology that is developed to improve the uptake of low doses of chemotherapy with at least 1000 times higher infiltration. The TSE adapts the electrical field to avoid unwanted destruction of both cancerous and healthy tissue. It has been shown to reduce necrosis and tissue damage, as well as change the cellular characteristics in the tumours to be eligible for immune responses.
The pancreatic cancer cases in
[1] https://www.futuremarketinsights.com/reports/pancreatic-cancer-market
For more information, please contact:
+46 (0)10-218 93 00
ir@chemotech.se
Certified Adviser:
E-mail: certifiedadviser@redeye.se
This disclosure contains information that ChemoTech is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on
ChemoTech is a Swedish medical technology company based in
https://news.cision.com/chemotech/r/pancreatic-cancer-patients-in-ukraine-treated-with-tumour-specific-electroporation---tse--are-contin,c3698820
https://mb.cision.com/Main/14967/3698820/1786195.pdf
https://news.cision.com/chemotech/i/shutterstock-1021932094,c3134549
(c) 2023 Cision. All rights reserved., source